Trial Profile

A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics of Single Oral Doses of Ozanimod in Healthy Adult Chinese Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 26 Mar 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ozanimod (Primary)
Indications Crohn's disease; Multiple sclerosis; Ulcerative colitis
Focus Pharmacokinetics
Sponsors Celgene Corporation

Most Recent Events

24 Mar 2021 Status changed from recruiting to completed.
21 Sep 2020 Planned End Date changed from 30 Nov 2020 to 12 Oct 2020.
21 Sep 2020 Planned primary completion date changed from 19 Sep 2020 to 26 Sep 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com